Abstract

Dengue and Zika viruses are closely related mosquito-borne flaviviruses responsible for major public health problems in tropical and sub-tropical countries. The genomes of both, dengue and zika viruses encodes 10 genes that are translated into three structural proteins (C, prM, and E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The non-structural protein 1 (NS1) is a highly conserved glycoprotein of approximately 48–50 KDa. In infected cells, NS1 is found as a homodimer associated with intracellular membranes and replication complexes, serving as a scaffolding protein in virus replication and morphogenesis. NS1 is secreted efficiently from infected cells as a hexamer and is found in patient's sera during the acute phase of the disease. NS1 detection in sera is a valuable diagnostic marker and immunization with NS1 has been shown to protect animal models from lethal challenges with dengue and Zika viruses. Nevertheless, soluble NS1 has been associated with severe dengue and anti-NS1 antibodies have been reported to cross-react with host platelets and endothelial cells and thus presumably contribute to pathogenesis. Due to the implications of NS1 in arbovirus pathogenesis and its relevance as vaccine candidate, we discuss the dual role that anti-NS1 antibodies may play in protection and disease and the challenges that need to be overcome to develop safe and effective NS1-based vaccines against dengue and Zika.

Highlights

  • Dengue is the most important mosquito-borne viral disease in humans

  • For as long as antibody-dependent enhancement (ADE) has been recognized as an immune mechanism that promotes severe dengue (DHF/DSS), efforts have been made to find alternative dengue virus (DENV) vaccine strategies to induce immune responses against antigens other than structural components of the DENV virion

  • The observation that both, structural proteins and the non-structural protein 1 (NS1) elicit strong humoral immune responses in infected individuals has prompted the development of vaccines against both DENV components

Read more

Summary

Introduction

Dengue is the most important mosquito-borne viral disease in humans. It is endemic in over 100 countries and it is estimated that nearly 2/3 of the world’s population lives in risk areas for this disease. The notion that anti-NS1 antibodies do participate in dengue pathogenesis resulted from experiments by Falconar, who showed that anti-NS1 monoclonal antibodies cross-react with human fibrinogen, thrombocytes and endothelial cells and produce hemorrhage in a mouse model [24].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call